JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. (Q53185401)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 October 2009

Language	Label	Description	Also known as
English	JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.	scientific article published on 22 October 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

1 reference

based on heuristic

inferred from title

chronic idiopathic myelofibrosis

1 reference

based on heuristic

inferred from title

genetic variation

1 reference

based on heuristic

inferred from title

1

object named as

A Tefferi

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

8

object named as

M R Litzow

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

author name string

T L Lasho

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

M M Patnaik

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

C M Finke

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

K Hussein

5

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

W J Hogan

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

M A Elliott

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

C A Hanson

9

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

A Pardanani

10

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

publication date

22 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

24

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

105-109

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

https://scigraph.springernature.com/pub.10.1038/leu.2009.225

0 references

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

21 January 2018

Expression of the JAK2 V617F mutation is not found in de novo AML and MDS but is detected in MDS-derived leukemia of megakaryoblastic nature

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

7 January 2021

based on heuristic

inferred from DOI database lookup

Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

7 January 2021

based on heuristic

inferred from DOI database lookup

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

7 January 2021

based on heuristic

inferred from DOI database lookup

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.225

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2009.225

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/19847199

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53185401&oldid=2139137193"